{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-048141","form_type":"8-K","ticker":"EMMA","cik":"0000822370","company_name":"Emmaus Life Sciences, Inc.","filed_at":"2022-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.229828+00:00","generated_at":"2026-06-24T00:10:12.628661+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Emmaus Life Sciences reports Q2 2022 net loss of $8.9M; warns of insufficient working capital for 12 months","bullets":["Net revenues Q2 2022 $4.3M, down 34% YoY from $6.5M; sequentially up 33% from Q1 2022 $3.2M.","Net loss Q2 2022 $8.9M ($0.18/sh) vs net income $2.5M ($0.05/sh) in Q2 2021.","Cash and equivalents $1.0M at June 30, 2022, down from $2.3M at Dec 31, 2021.","Management says working capital insufficient for next 12 months without restructuring or new financing.","In discussions to restructure indebtedness; awaiting Saudi marketing approval decision."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-048141","json":"https://secwatch.observer/filing/0001213900-22-048141.json","markdown":"https://secwatch.observer/filing/0001213900-22-048141.md","text":"https://secwatch.observer/filing/0001213900-22-048141.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/822370/000121390022048141/0001213900-22-048141-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/822370/000121390022048141/ea164264-8k_emmauslife.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:10:12.628661+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}